Medical Advocates
Atazanavir (Reyataz)
 
Journal Citations
Therapeutic Strategies

First Line Therapy            
Simplification Therapy               
Salvage Therapy
 Multiple Virological Failures
 Metabolic Disorders
 HIV/HCV Coinfection



 

  
ATZ Journal Main Page New/Newsworthy Home Page      
Last updated:  November 17, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
First Line Therapy
       
  Atazanavir: a new protease inhibitor to treat HIV infection.
 Musial BL, Chojnacki JK, Coleman CI. 
Am J Health Syst Pharm. 2004 Jul 1;61(13):1365-74.
Abstract
Simplification Therapy
       
 
 
Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring.
 Rodríguez-Nóvoa S, Morello J, Barreiro P, et al
AIDS Res Hum Retroviruses. 2008 May 28.
 Abstract

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after
sustained virologic suppression.
 Swindells S, DiRienzo AG, Wilkin T, et al 
JAMA. 2006 Aug 16;296(7):806-14
 Abstract
Salvage Therapy
       
 
FULL-TEXT PDF ARTICLE
 Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and
lopinavir/ritonavir combination therapy.
Choi H, Jeong SJ, Lee HS, et al  
J Korean Med Sci. 2008 Aug;23(4):737-9
Paper

A WEEK IN REVIEW FEATURED REPORT
 Decrease of atazanavir and lopinavir plasma concentrations in a boosted double HIV-protease
inhibitor salvage regimen.
 von Hentig N, Kaykhin P, Stephan C, et al
 Antimicrob Agents Chemother. 2008 Apr 14
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients
with multiple treatment failures: randomized ANRS 107 trial.
 Piketty C, Gerard L, Chazallon C, et al 
Antivir Ther. 2006;11(2):213-21.
 Abstract
Multiple Virologic Failures
       
  Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing
multiple virological failures.
 Johnson M, Grinsztejn B, Rodriguez C,
AIDS. 2005 Apr 29;19(7):685-694.
 Abstract
Metabolic Disorders
       
 
A WEEK IN REVIEW FEATURED REPORT
Improvement in Insulin Sensitivity and Dyslipidemia in Protease Inhibitor-Treated Adult Male
Patients After Switch to Atazanavir/Ritonavir.
 Busti AJ, Bedimo R, Margolis DM, Hardin DS.
J Investig Med. 2008 Feb;56(2):539-544.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
 Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active
antiretroviral therapy in patients with human immunodeficiency virus.
 Nguyen ST, Eaton SA, Bain AM, et al
Pharmacotherapy. 2008 Mar;28(3):323-30.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1
infected subjects.
 Guffanti M, Caumo A, Galli L, et al
Eur J Endocrinol. 2007 Apr;156(4):503-509
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Switching to Atazanavir Improves Metabolic Disorders in Antiretroviral-Experienced
Patients With Severe Hyperlipidemia.
 Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al 
J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):174-180
 Abstract
HIV/HCV Coinfection
       
  Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following
initiation of pegylated-interferon and ribavirin.
Rodríguez-Nóvoa S, Morello   
 AIDS. 2008 Nov 30;22(18):2535-7
 Abstract

ATZ Journal Main Page New/Newsworthy Home Page      

Atazanavir Journal Citations
Therapeutic Strategies